Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) CEO Jay Duker acquired 1,500 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were bought at an average cost of $13.15 per share, with a total value of $19,725.00. Following the completion of the acquisition, the chief executive officer directly owned 100,665 shares in the company, valued at approximately $1,323,744.75. This represents a 1.51% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Eyepoint Pharmaceuticals Trading Up 1.9%

Shares of EYPT traded up $0.25 during trading hours on Monday, reaching $13.45. 1,106,965 shares of the stock traded hands, compared to its average volume of 1,445,532. The stock has a fifty day simple moving average of $15.32 and a 200 day simple moving average of $14.49. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $19.11. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -4.26 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The business had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%. Analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Chardan Capital upped their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. HC Wainwright boosted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Finally, Citigroup lifted their price objective on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $32.20.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Franklin Resources Inc. boosted its position in Eyepoint Pharmaceuticals by 3.6% during the second quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company’s stock worth $40,474,000 after purchasing an additional 151,262 shares during the period. Rhumbline Advisers raised its position in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after purchasing an additional 9,548 shares during the period. American Century Companies Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 57.8% during the 2nd quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock valued at $636,000 after buying an additional 24,752 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Eyepoint Pharmaceuticals by 215.4% during the 2nd quarter. XTX Topco Ltd now owns 137,950 shares of the company’s stock valued at $1,298,000 after buying an additional 94,210 shares in the last quarter. Finally, Inceptionr LLC purchased a new stake in shares of Eyepoint Pharmaceuticals during the 2nd quarter valued at approximately $131,000. 99.41% of the stock is currently owned by institutional investors.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.